FDA Accepts UroGen’s UGN-103 Application for Review
The FDA accepted UroGen Pharma’s new drug application for UGN-103, an investigational treatment for adults with recurrent LG-IR-NMIBC.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.